Brief: Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules
20/11/2025 13:54
Neurocrine Biosciences Inc NBIX.O: NEUROCRINE BIOSCIENCES ANNOUNCES PUBLICATION OF LANDMARK NARRATIVE REVIEW ON FDA-APPROVED VMAT2 INHIBITORS DEMONSTRATING UNIQUE PROFILE OF INGREZZA® (VALBENAZINE) CAPSULES Source text: ID:nPnbNnBSBa Further company coverage: NBIX.O
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall